CALINA Study Shows Positive Efficacy and Safety Data for a Novel Treatment for Small Babies

Swiss TPH "Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety. The trial was conducted in several African countries. Swiss TPH was in charge of carrying out the study in the Democratic Republic of the Congo."

• Swiss TPH